Login to Your Account

Bicycle's series B adds $52M as the rubber hits the road

By Cormac Sheridan
Staff Writer

Thursday, June 1, 2017

DUBLIN – Bicycle Therapeutics Ltd. received another hefty dose of validation for its constrained peptide technology in the form of a £40 million (US$51.5 million) series B round, which will enable it to take multiple programs into clinical development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription